In a post-hoc investigation of diabetic participants in phase 3 trials, ixekizumab led to high proportions of Psoriasis Area and Severity Index amelioration.
During the COVID-19 pandemic lockdowns, results of the Dermatology Life Quality Index may have been altered by an increased number of “not-relevant” responses. DLQI-scores could be underestimated.
Gene expression patterns differed between lesional and non-lesional skin of patients with generalised pustular psoriasis with an upregulation.
Fitusiran prophylactic therapy reduced the ABR in severe haemophilia A or B patients without inhibitors. Quality of life increase was associated with fitusiran therapy.
The 5-azacitidine, venetoclax, and magrolimab combo had good response rates in newly diagnosed older, unfit, or TP53-mutated AML patients.
rFVIIIFc therapy realised immune tolerance in approximately 2 out of 3 patients with severe haemophilia A and high-titre inhibitors who underwent first ITI therapy.
Results from the POLARIX trial suggest that Pola-R-CHP may be the preferred first-line therapy for patients with diffuse large B-cell lymphoma.
Therapy de-escalation in patients with ALL and a low-risk MRD profile was safe, 10-year follow-up results of the UKALL 2003 trial show.
The final trial results showed that younger and older patients with FLT3-ITD-mutated AML benefitted from adding midostaurin to intensive chemotherapy.
The large, population-based study showed prevalence in 40 years+ patients. Approximately 1 out of 3 smouldering MM patients may progress towards MM.
Teclistamab was safe and efficacious in relapsed/refractory multiple myeloma patients. Phase 1/2 trial showed durable and deepening responses.
CHIP was related to decreased risk of AD and its neuropathological changes. Mutated haematopoietic stem cells were detected in the brains of CHIP carriers.
A quizartinib, venetoclax and decitabine combo was highly active in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukaemia.
A JAK2V617F variant with an allele frequency of over 50% is associated with a higher risk of venous thrombosis in patients with polycythaemia vera (PV).
Cladribine plus low-dose cytarabine plus venetoclax alternated with 5-azacytidine plus venetoclax showed encouraging efficacy in newly diagnosed AML patients.
Treatment with fitusiran for prophylaxis resulted in a lower rate of bleeding events and improved health quality of life in haemophilia A or B patients with inhibitors.
Significant disparities in health outcomes were observed across race, ethnicity, and socioeconomic status (SES) in patients with acute lymphoblastic leukaemia (ALL).
CPX-351 therapy did not result in different overall survival (OS) outcomes or response rates than venetoclax plus HMA therapy in patients with acute myeloid leukaemia (AML) between 60 and 75 years of age.
The combination regimen of low-dose tacrolimus plus high-dose dexamethasone provides benefits over high-dose dexamethasone monotherapy in patients with immune thrombocytopenia (ITP), promising first-line treatment for patients with ITP.
The dual therapy demonstrated durable and deep responses in heavily pre-treated patients with refractory MM. The combination regimen was tolerable and did not show overlapping toxicity. It is therefore a promising option for treating patients with MM.